Organization

CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC

According to 2025 Medicare claims, CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC (NPI: 1316378789) practices clinical laboratory (billing independently) in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC (NPI: 1316378789; TIN: 452172398) and primary practice location at 44060-4806.

The organization's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,785 traditional Medicare patients, billed 97,117 HCPCS/CPT codes, and received $1,523,322 in Medicare payments. The top billing code was 87640 (Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $39,683 to $1,523,322. Concurrently, this provider has fewer than 5 years of reported Part D prescription costs data, so a reliable trend cannot be assigned. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.4M$2.8M2015 Medicare payment: $39,683 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $75,045 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,083,391 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,456,853 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,772,445 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,820,953 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,523,322 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201555109$39,683
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
20191291,805$75,045
20202,36823,477$1,083,391
20212,25141,058$1,456,853
20222,89355,965$1,772,445
20233,221104,666$2,820,953
20242,78597,117$1,523,322

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

No connected Part D records

No connected Part D records

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
87640Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique1,0801,255$34
87798Detection test by nucleic acid for organism, amplified probe technique1,09316,090$34
82140Ammonia level1,2902,706$14
80053Blood test, comprehensive group of blood chemicals1,0521,951$10
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count1,2722,634$8

Top 5 Part D drugs in 2024

By total drug costs.

No connected Part D drug-level records for 2024.

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC?

Tedicare shows public-source Medicare data for CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC (NPI 1316378789), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC?

CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC is linked to CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC (billing NPI 1316378789) in the available physician profile data.

Does CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.